Bibliography
[1] Cystic fibrosis mutation database. Hospital for Sick Children,
Toronto. www.genet.sickkids.on.ca. Accessed September 29, 2018
[2] David A Stoltz, David K Meyerholz, Michael J Welsh, Origins of
cystic fibrosis lung disease N Engl J Med 2015 Jan 22;372(4):351-62.
doi: 10.1056/NEJMra1300109.
[3] Bouhuys A, van Lennep H. Effect of body posture on gas
distribution in the lungs. J Appl Physiol. 1962 Jan;17:38-42. doi:
10.1152/jappl.1962.17.1.38.
[4] Sivagurunathan Sutharsan, Edward F McKone, Damian G Downey,
Jamie Duckers, Gordon MacGregor, Elizabeth Tullis, Eva Van Braeckel,
Claire E. Wainwright, Danie Watson, Neil Ahluwalia et al. Efficacy and
safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor
plus ivacaftor in people with cystic fibrosis homozygous for
F508del-CFTR: a 24-week, multicentre, randomised, double-blind,
active-controlled, phase 3b trial. Lancet Respir Med. 2022
Mar;10(3):267-277. doi: 10.1016/S2213-2600(21)00454-9.
[5] Simon Y Graeber, Diane M Renz, Mirjam Stahl, Sophia T
Pallenberg, Olaf Sommerburg, Lutz Naehrlich, Julian Berges, Martha
Dohna, Felix C Ringshausen, Felix Doellinger et al. Effects of
Elexacaftor/Tezacaftor/Ivacaftor Therapy on Lung Clearance Index and
Magnetic Resonance Imaging in Patients with Cystic Fibrosis and One or
Two F508del Alleles. Am J Respir Crit Care Med 2022 May 10. doi:
10.1164/rccm.202201-0219OC.
[6] Paul D Robinson, Philipp Latzin, Sylvia Verbanck, Graham L Hall,
Alexander Horsley, Monika Gappa, Cindy Thamrin, Hubertus G M Arets, Paul
Aurora, Susanne I Fuchs et al. Consensus statement for inert gas washout
measurement using multiple- and single- breath tests. Eur Respir J. 2013
Mar;41(3):507-22. doi: 10.1183/09031936.00069712.
[7] A R Horsley, P M Gustafsson, K A Macleod, C Saunders, A P
Greening, D J Porteous, J C Davies, S Cunningham, E W F W Alton, J A
Innes. Lung clearance index is a sensitive, repeatable and
practicalmeasure of airways disease in adults with cystic fibrosis.
Thorax 2008 Feb;63(2):135-40. doi: 10.1136/thx.2007.082628.
[8] Harm A W M Tiddens, Detecting early structural lung damage in
cystic fibrosis. Pediatr Pulmonol 2002; 34: 228–231. doi:
10.1002/ppul.10134.
[9] Gustafsson PM, Aurora P, Lindblad A. Evaluation of ventilation
maldistribution as an early indicator of lung disease in children with
cystic fibrosis. Eur Respir J 2003; 22: 972–979. doi:
10.1183/09031936.03.00049502.
[10] P Aurora, P Gustafsson, A Bush, A Lindblad, C Oliver, C E
Wallis, J Stocks. Multiple breath inert gas washout as a measure of
ventilation distribution in children with cystic fibrosis. Thorax 2004
Dec;59(12):1068-73. doi: 10.1136/thx.2004.022590.
[11] O’Neill K, Johnston E, Tunney MM, Stephen Rowan, Damian G.
Downey,
Jacqueline Rendall, Alastair Reid, Ian Bradbury, J. Stuart Elborn, Judy
M. Bradley. Lung clearance index (LCI): a sensitive outcome measure in
adults and children with cystic fibrosis (CF). Phys Ther Rev 2014; 19:
57.
[12] Esther Oude Engberink, Felix Ratjen, Stephanie D Davis, George
Retsch-Bogart, Reshma Amin, Sanja Stanojevic. Inter-test reproducibility
of the lung clearance index measured by multiple breath washout. Eur
Respir J. 2017 Oct 5;50(4):1700433. doi: 10.1183/13993003.00433-2017.
[13] K. O’Neill, J. Elborn, E. Johnston, J. Bradley, M. Tunney.
Changes in lung clearance index during periods of stability and
pulmonary exacerbation. Pediatr Pulmonol 2012; 47: Suppl. 35, 352–353.
[14] O’Neill K, Johnston E, Tunney M, Stuart Elborn J, Bradley J.
Lung clearance index (LCI) during and following a pulmonary exacerbation
(PEx) in patients with CF. J Cyst Fibros 2012; 11: Suppl. 1, S97.
[15] C M Owens, P Aurora, S Stanojevic, A Bush, A Wade, C Oliver, A
Calder, J Price, S B Carr, A Shankar, Janet Stocks; London Cystic
Fibrosis Collaboration. Lung clearance index and HRCT are complementary
markers of lung abnormalities in young children with CF. Thorax 2011
Jun;66(6):481-8. doi: 10.1136/thx.2010.150375.
[16] Michael D Parkins, Jacqueline C Rendall, J Stuart Elborn.
Incidence and risk factors for pulmonary exacerbation treatment failures
in patients with cystic fibrosis chronically infected with Pseudomonas
aeruginosa. Chest 2012 Feb;141(2):485-493. doi: 10.1378/chest.11-0917
[17] J Michael Collaco, Deanna M Green, Garry R Cutting, Kathleen M
Naughton, Peter J Mogayzel Jr. Location and duration of treatment of
cystic fibrosis respiratory exacerbations do not affect outcomes. Am J
Respir Crit Care Med. 010 Nov 1;182(9):1137-43. doi:
10.1164/rccm.201001-0057OC.
[18] Claudia L Ordoñez, Noreen R Henig, Nicole Mayer-Hamblett, Frank
J Accurso, Jane L Burns, James F Chmiel, Cori L Daines, Ronald L Gibson,
Sharon McNamara, George Z Retsch-Bogart et al. Inflammatory and
microbiologic markers in induced sputum after intravenous antibiotics in
cystic fibrosis. Am J Respir Crit Care Med. 2003 Dec 15; 168(12):1471-5.
doi: 10.1164/rccm.200306-731OC.
[19] Don B Sanders, Rachel C L Bittner, Margaret Rosenfeld, Lucas R
Hoffman, Gregory J Redding, Christopher H Goss. Failure to recover to
baseline pulmonary function after cystic fibrosis pulmonary
exacerbation. Am J Respir Crit Care Med. 2010 Sep 1;182(5):627-32. doi:
10.1164/rccm.200909-1421OC.
[20] Donald R VanDevanter, Mary A O’Riordan, Jeffrey L Blumer,
Michael W Konstan. Assessing time to pulmonary function benefit
following antibiotic treatment of acute cystic fibrosis exacerbations.
Respir Res. 2010 Oct 6;11(1):137. doi: 10.1186/1465-9921-11-137.
[21] Paul D Robinson, Peter Cooper, Peter Van Asperen, Dominic
Fitzgerald, Hiran Selvadurai. Using index of ventilation to assess
response to treatment for acute pulmonary exacerbation in children with
cystic fibrosis. Pediatr Pulmonol. 2009 Aug;44(8):733-42. doi:
10.1002/ppul.20956.
[23] Eef Vanderhelst, Liesbeth De Meirleir, Daniel Schuermans, Anne
Malfroot, Walter Vincken, Sylvia Verbanck. Evidence of an acinar
response following treatment for exacerbation in adult patients with
cystic fibrosis. Respiration. 2014;87(6):492-8. doi: 10.1159/000360772.
[23] Liam Welsh, Christopher Nesci, Haily Tran, Marisol Tomai,
Sarath Ranganathan. Lung clearance index during hospital admission in
school-age children with cystic fibrosis. J Cyst Fibros. 2014
Dec;13(6):687-91. doi: 10.1016/j.jcf.2014.05.012.
[24] Sophie Yammine, Anja Bigler, Carmen Casaulta, Florian Singer,
Philipp Latzin. Reasons for heterogeneous change in LCI in children with
cystic fibrosis after antibiotic treatment. Thorax. 2014 Feb;69(2):183.
doi: 10.1136/thoraxjnl-2013-204283.
[25] Nicole Sonneveld, Sanja Stanojevic, Reshma Amin, Paul Aurora,
Jane Davies, J. Stuart Elborn, Alex Horsley, Philipp Latzin, Katherine
O’Neill, Paul Robinson et al. Lung clearance index in cystic fibrosis
subjects treated for pulmonary exacerbations. Eur Respir J. 2015
Oct;46(4):1055-64. doi: 10.1183/09031936.00211914.
[26] Button BM, Wilson C, Dentice R, Cox NS, Middleton A, Tannenbaum
E, Bishop J, Cobb R, Burton K, Wood M. Physiotherapy for cystic fibrosis
in Australia and New Zealand: A clinical practice guideline.
Respirology. 2016 May;21(4):656-67. doi: 10.1111/resp.12764. Epub 2016
Apr 18
[27] Paul D. Robinson, Philipp Latzin, Sylvia Verbanck, Graham L.
Hall, Alexander Horsley, Monika Gappa, Cindy Thamrin, Hubertus G M
Arets, Paul Aurora, Susanne I Fuchs et al. Consensus statement for inert
gas washout measurement using multiple- and single- breath tests
European Respiratory Journal 2013 41: 507-522; DOI:
10.1183/09031936.0006971
[28] Pinelopi Anagnostopoulou, Philipp Latzin, Renee Jensen, Mirjam
Stahl, Alana Harper, Sophie Yammine, Usemann J, Foong RE, Spycher B,
Hall GL et al. Normative data for multiple breath washout outcomes in
school-aged Caucasian children. Eur Respir J. 2020 Apr 3;55(4):1901302.
doi: 10.1183/13993003.01302-2019.
[29] Philip H Quanjer, Sanja Stanojevic, Tim J Cole, Xaver Baur,
Graham L Hall, Bruce H Culver, Paul L Enright, John L Hankinson, Mary S
M Ip, Jinping Zheng et al. Multi-ethnic reference values for spirometry
for the 3-95-yr age range: the global lung function 2012 equations. Eur
Respir J. 2012 Dec;40(6):1324-43. doi: 10.1183/09031936.00080312.
[30] Hatziagorou E, Avramidou V, Kirvassilis F, Tsanakas J. Use of
lung clearance index to assess the response to intravenous treatment in
cystic fibrosis Use of lung clearance index to assess the response to
intravenous treatment in cystic fibrosis. Hippokratia. 2015
Jan-Mar;19(1):47-52.
[31] Jonathan H Rayment, Sanja Stanojevic, Stephanie D Davis, George
Retsch-Bogart, Felix Ratjen. Lung clearance index to monitor treatment
response in pulmonary exacerbations in preschool children with cystic
fibrosis. Thorax. 2018 May;73(5):451-458. doi:
10.1136/thoraxjnl-2017-210979.
[32] Marcus Svedberg, Per M Gustafsson, Paul D Robinson, Monica
Rosberg, Anders Lindblad. Variability of lung clearance index in
clinically stable cystic fibrosis lung disease in school age children. J
Cyst Fibros. 2018 Mar;17(2):236-241. doi: 10.1016/j.jcf.2017.08.004.
[33] Dong K, Huh SM, Lam GY, Jang J, Franciosi AN, Wilcox PG,
Bradley S Quon. Pulmonary exacerbation inflammatory phenotypes in adults
with cystic fibrosis. J Cyst Fibros. 2022 Dec 24:S1569-1993(22)01433-3.
doi: 10.1016/j.jcf.2022.12.013.
Acknowledgements None.
Authors’ contributions MDM, EM and LC conceived the study. MDM
and AB wrote the manuscript. MDM ,LC and AF collected data. RC and AGF
conceived and directed the work thanks to their knowledge of the subject
matter. All authors analyzed and interpreted patients’ data, read and
approved the final manuscript.
Funding None
Availability of data and materials The datasets used and/or
analysed during the current study are available from the corresponding
author on reasonable request.
Ethics approval and consent to participate Local ethics
committees approved the study (n° 2819_OPBG_2022). Parental consent
was not required because this is a retrospective study and data were
anonymized.
Consent for publication Not applicable.
Competing interests The authors declare that they have no
competing interests.